Research Article

***Acinetobacter* Infections among Adult Patients in Qatar: A 2-Year Hospital-Based Study**

Musaed Saad Al Samawi,¹ Fahmi Yousef Khan,² Yasser Eldeeb,¹
Muna Almaslamani,³ Abdullatif Alkhal,³ Hussam Alsoub,³ Wissam Ghadban,⁴
Faraj Howady,³ and Samar Hashim³

¹Infectious Diseases Division, Department of Medicine, Al Khor Hospital, Al Khor, Qatar

²Department of Medicine, Hamad General Hospital, Doha, Qatar

³Infectious Diseases Division, Department of Medicine, Hamad General Hospital, Doha, Qatar

⁴Department of Medicine, Al Khor Hospital, Al Khor, Qatar

Correspondence should be addressed to Musaed Saad Al Samawi; dr_samawi@yahoo.com

Received 21 February 2016; Revised 23 May 2016; Accepted 2 June 2016

Academic Editor: Giordano Dicuonzo

Copyright © 2016 Musaed Saad Al Samawi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This retrospective study was conducted at Hamad General Hospital, Qatar, to describe the demographic data, clinical features underlying diseases, antimicrobial susceptibility, and outcome of *A. baumannii* infection. It involved all adult patients 15 years of age or older who were managed at Hamad General Hospital for *A. baumannii* infection from January 1, 2012, to December 31, 2013. We identified a total of 239 patients with *A. baumannii* infection, of which 182 (76.2%) were males. The mean age was 49.10 ± 19.57 years. The majority of the episodes (25.1%) occurred in elderly patients (≥ 65 years) and the most commonly identified site of *A. baumannii* infection was the respiratory tract, 117 (48.9%). Most episodes of infection, 231 (96.7%), were hospital-acquired and high rate of nosocomial infections occurred in the medical intensive care unit, 66 (28.6%). All patients had underlying medical conditions. Maximum resistance was seen to cefotaxime, 147 (58.3%), and minimum resistance was seen to colistin, 2 (1.4%). Of the 239 isolates, 102 (42.7%) were susceptible and 137 (57.3%) were multidrug-resistant. The in-hospital mortality in our study was 31%. Male gender, multidrug resistance, and septic shock were found to be independent mortality predictors.

1. Introduction

Acinetobacter baumannii is an aerobic Gram-negative coccobacillus that has emerged as an important opportunistic pathogen, especially among debilitated patients, and a common cause of hospital-acquired infections, such as bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection, especially in intensive care units [1, 2]. *A. baumannii* is also a cause of community-acquired infections in many countries [3, 4]. The epidemic potential and the clinical severity of *A. baumannii* infections are related to resistance of the isolates to most classes of antibiotics through multiple mechanisms [1, 2].

In Qatar, the epidemiology of *A. baumannii* infection has not been studied in detail before. Only few reports have been published [5, 6]. The aim of this study was to describe the demographic data, clinical features, underlying diseases,

antimicrobial susceptibility, and outcome of *A. baumannii* infection at Hamad General Hospital, Qatar.

2. Materials and Methods

2.1. Design and Setting. This hospital-based retrospective study was conducted at Hamad General Hospital. It involved all adult patients 15 years of age or older who were managed at Hamad General Hospital for *A. baumannii* infection from January 1, 2012, to December 31, 2013.

2.2. Case Definition. Hospital-acquired infection was defined as occurrence of infection 48 hours or more after hospital admission or within 48 h after discharge or if it was preceded by an invasive procedure [6]. Community-acquired infection was considered if the positive culture was obtained within

the first 48 h of hospitalization and the patient was not hospitalized in the preceding month [6]. Empirical antimicrobial therapy was defined as treatment that included at least one antibiotic and that was started no later than 24 h after the blood sample for culture had been drawn. This therapy was deemed inadequate if the antibiotics were administered after 24 h of blood sample extraction and/or when the dosage, route, and duration of treatment were not in accordance with current medical standards [7]. *A. baumannii* infection was defined as any patient who had *A. baumannii* isolated from any site in conjunction with a compatible clinical picture warranting treatment with antibiotics effective against *A. baumannii* [8]. Disease severity was estimated by the presence of sepsis or septic shock, which was defined according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Sepsis was defined as the systemic inflammatory response (SIRS) to infection and septic shock was defined as sepsis- (SIRS-) induced hypotension despite adequate fluid resuscitation along with presence of perfusion abnormalities that may include, but are not limited to, lactic acidosis, oliguria, or an acute alteration in mental status. Patients receiving inotropic or vasopressor agents may no longer be hypotensive by the time they manifest hypoperfusion abnormalities or organ dysfunction, yet they would still be considered having septic (SIRS) shock [9]. *A. baumannii* isolates were considered multidrug resistance (MDR) if they exhibit resistance to carbapenem or resistance to at least one agent in three or more antibiotic classes [10]. The primary outcome was crude in-hospital mortality, which was defined as all causes of death during admission (i.e., infection-related mortality and mortality due to other causes).

Antibiotic Susceptibility Testing. After *A. baumannii* had been isolated from a range of clinical specimens, all isolates underwent susceptibility testing by the broth microdilution method (BD Phoenix; Becton Dickinson, Franklin Lakes, NJ, USA). The susceptibility breakpoints are defined by the Clinical and Laboratory Standards Institute [11].

2.3. Case Identification and Data Collection. All cases were identified from the hospital's microbiology records. The files and the electronic records of the patients were reviewed to identify infections and to retrieve the following data: demographic information; underlying conditions such as prior MRSA colonization; type of infection (community-acquired or hospital-acquired); antimicrobial susceptibility; and the outcome.

2.4. Data Analysis. Quantitative variables are expressed as mean $\pm$ standard deviations. In identifying the independent risk factors for in-hospital mortality, logistic regression model was used for univariate and multivariate analysis. The following variables were analyzed: age, sex, nationality, clinical picture, presence of other medical conditions, multidrug resistance isolates, and severity of infection. Univariate logistic regression was performed to determine the probable predictors of mortality among patients with *A. baumannii*

infection. All potential risk factors significant at the 0.1 level in the univariate analysis were entered in the multiple logistic regression to identify the independent predictors of mortality at $P < 0.05$. The data were analyzed with SPSS software (v 17; IBM Corp., Armonk, NY, USA).

2.5. Research Committee Approval. As the study was retrospective, a waiver of informed consent was obtained from the research committee at Hamad Medical Corporation.

3. Results

During the period of study, a total of 372 consecutive *A. baumannii* isolates were collected by the microbiology department at Hamad General Hospital, which represent 2.8% (372/13286) of total isolates and 3.6% (372/10333) of Gram-negative isolates in our hospital. Based on evaluation of clinical charts, 239/372 (64.3%) isolates were classified as infection and 133/372 (35.7%) were considered colonizers. Of the 239 patients with *Acinetobacter* infection, 182 (76.2%) were males and 166 (66.5%) were non-Qataris. The mean age ($\pm$ standard deviation (SD)) was 49.10 ± 19.57 years (range: 14–99 years). Table 1 illustrates the demographic and clinical data of the 239 patients. Sixty episodes (25.1%) occurred in elderly patients (≥ 65 years). Table 2 describes the distribution of the 239 infections among different age groups.

The most commonly identified sites of *A. baumannii* infection were the respiratory tract, 117 (48.9%), followed by urinary tract, 42 (17.6%), and blood, 40 (16.7%). The sites of *A. baumannii* infection are listed in Table 3. Most episodes of infection, 231/239 (96.7%), were hospital-acquired and high rate of nosocomial infections occurred in the medical intensive care unit (MICU), 66/231 (28.6%) (Tables 1 and 4).

All patients had an underlying medical conditions; 156 (65.3%) were on mechanical ventilation and 148 (61.9%) were on enteral feeding (Table 1). Maximum resistance was seen to cefotaxime, 147 (58.3%), and minimum resistance was seen to colistin, 2 (0.8%).

Of the 239 isolates, 102 (42.7%) were susceptible and 137 (57.3%) were multidrug-resistant (MDR). From these 137 MDR isolates, 2/137 (1.4%) showed resistance to colistin and 5/137 (3.6%) were resistant to tigecycline. All community-acquired isolates were susceptible except for one. The *in vitro* activity of individual antimicrobial agents against *A. baumannii* clinical isolates is summarized in Table 5.

The crude in-hospital mortality in our study was 65/239 (31%). By the univariate analysis, the following variables were associated with increased in-hospital mortality: old age (>65 year), male gender, pneumonia as underlying disease, multidrug resistance, septic shock, and inadequate therapy. Only male gender, multidrug resistance, and septic shock were found to be independent predictors of in-hospital mortality by multivariate logistic regression analysis (Table 6).

4. Discussion

To our knowledge this is the first report detailing the demographic data, clinical features, underlying diseases,

TABLE 1: Demographic and clinical data of the 239 patients involved in this study.

Variable	Number (%) / mean $\pm$ SD
<i>Gender</i>	
M	182 (76.2%)
F	57 (23.8%)
Age (mean $\pm$ SD)	49.10 $\pm$ 19.57 years
<i>Nationality</i>	
Qatari	73 (30.5%)
Non-Qatari	166 (66.5%)
<i>Underlying medical conditions</i>	
Prior MRSA colonization	18 (7.5%)
ICU stay	43 (17.9%)
Bed-ridden	51 (21.3%)
Prior <i>Acinetobacter</i>	15 (6.3%)
Tracheostomy	76 (31.7%)
Mechanical ventilation	156 (65.3%)
Pneumonia	108 (45.2%)
Diabetes mellitus	86 (35.9%)
Malignancy	27 (11.3%)
Recent surgery	86 (35.9%)
Invasive procedure	147 (61.5%)
Hemodialysis	43 (17.9%)
Previous antibiotic usage	105 (43.9%)
Enteral feeding	148 (61.9%)
<i>Infection setting</i>	
Hospital-acquired	231 (96.7%)
Community-acquired	8 (3.3%)
<i>Severity</i>	
Without sepsis	166 (69.4%)
Sepsis	3 (1.3%)
Septic shock	70 (29.3%)
<i>Adequacy of treatment</i>	
Adequate	90 (37.7%)
Inadequate	149 (26.3%)
<i>Outcome</i>	
Survived	174 (69%)
Died	65 (31%)

TABLE 2: Number of isolates among different age groups.

Age groups	Number of isolates (%)
15–24	28 (11.7%)
25–34	43 (18.0%)
35–44	31 (13.0)
45–54	38 (15.9%)
55–64	39 (16.3%)
≥ 65	60 (25.1%)
Total	239 (100%)

antimicrobial susceptibility, and outcome of *A. baumannii* infection in Qatar.

TABLE 3: Sites of infection.

Primary infection	Number (%) /
Blood	40 (16.7%)
Respiratory tract	117 (48.9%)
Urine	42 (17.6%)
Wound swab	25 (10.5%)
Tissue biopsy	5 (2.1%)
Abdomen drain fluid	4 (1.7%)
Peritoneal fluid	4 (1.7%)
CSF	1 (0.4%)
Synovial fluid	1 (0.4%)
Total	239 (100%)

TABLE 4: Hospital-acquired isolates in different wards.

Ward	Number of isolates
Medical ICU	66 (28.6%)
Trauma ICU	64 (27.7%)
Surgical ICU	22 (9.5%)
Medical ward	40 (17.3%)
Surgical ward	39 (16.9%)
Total	231 (100%)

TABLE 5: Drug resistance of *A. baumannii*.

Drug	Drug resistance
Amikacin	82 (32.5%)
Gentamicin	116 (46.1%)
Ceftazidime	75 (29.8%)
Ceftriaxone	95 (37.7%)
Cefotaxime	147 (58.3%)
Septtrin	94 (37.3%)
Cefepime	115 (45.6%)
Colistin	2/137 (1.4%)
Meropenem	115 (45.6%)
Imipenem	89 (35.1%)
Tigecycline	5/137 (3.6%)
Piperacillin/tazobactam	126 (50%)
Ciprofloxacin	118 (46.8%)
Levofloxacin	60 (33.8%)

TABLE 6: Results of multivariate analysis of predictors of in-hospital mortality.

Variable	Adjusted odds ratio (95% CI)	P value
Male gender	2.5 (1.33–4.62)	0.004
Multidrug resistance	2.2 (1.19–3.94)	0.01
Septic shock	0.26 (0.25–0.72)	0.02

As noted, most of our findings are consistent with several reports worldwide; for example, *A. baumannii* infection occurred in the elderly, mainly male patients; the vast majority of cases were hospital-acquired, affecting critically

ill patients, especially those admitted into the intensive care units [1–3, 12–15].

Our results are, however, different from other studies in antimicrobial susceptibility pattern of *A. baumannii* isolates. These findings are the most relevant issue in this study and deserve special attention especially resistance pattern of the isolates towards carbapenems. The emergence of multidrug-resistant (MDR) isolates significantly limits effective therapeutic options. Therefore, monitoring antibiotic resistance patterns of this organism over time may provide useful information regarding its treatment policy. In the present study the prevalence of MDR among *A. baumannii* isolates accounted for 57.3% of the total, and the resistance to carbapenems represented 45.6% of total cases. These findings are less than those reported in India, Pakistan, Iran, Libya, Saudi Arabia, Greece, Turkey, Spain, and Italy [12, 14–24]. This findings are, however, alarming, suggesting the emergence of carbapenem-resistant *A. baumannii* and demonstrating the potential for this pathogen to become a major cause of nosocomial infections in Qatar; in addition, since the prevalence of MDR *A. baumannii* in Qatar was not determined before, our data can be used as a reference to assess any increase in the prevalence of resistant *Acinetobacter* in the future.

It has become increasingly clear that resistance development in *A. baumannii* is multifactorial and could be mediated by several mechanisms including (i) decreased permeability of antibiotics due to porin loss, (ii) alterations in penicillin-binding proteins, (iii) efflux pump and integrons, and (iv) hydrolysis of β -lactams by β -lactamases encoded by either plasmids or chromosome [25–27]. As noted, our study was descriptive, and there was data lacking on molecular epidemiology. Thus, we are unable to investigate the molecular basis of resistance among our isolates.

Other finding in our study which deserves attention is susceptibility pattern of *A. baumannii* isolates towards colistin and tigecycline. Literature data on the *in vitro* activity of tigecycline and colistin against *A. baumannii* shows variable susceptibility. Concerning tigecycline, 3.6% of our isolates were nonsusceptible, which is less than the proportions from Italy, India, and Taiwan [15, 28, 29] but similar to those reported in Turkey, Greece, and Thailand [30–32]. On the other hand, with few exceptions [33], recent reports show high antimicrobial activities of colistin against *A. baumannii* isolates, in agreement with our findings [32, 34]. These data suggest that tigecycline and colistin can be used effectively against MDR *A. baumannii* isolates in our hospital; however resistance rates should be monitored closely.

The crude mortality of *A. baumannii* infection varies ranging from 26 to 68% [13]. In our study, in-hospital mortality was 31% (65/239) which falls within the above-mentioned range. Although drug resistance of *A. baumannii* is a recognized problem, the effect of MDR *A. baumannii* infections on patient outcomes remains controversial [35]. By univariate analysis, we recognized several clinical variables as probable predictors of in-hospital mortality; only male gender, multidrug resistance, and septic shock were found to be independent predictors of in-hospital mortality by multivariate logistic regression analysis.

This study has several limitations that need to be considered when interpreting these data. First, the study was retrospective. Second, it is small and hospital-based. Third, the study period was short. Fourth, data on molecular epidemiology of *A. baumannii* are lacking.

Despite these limitations, this study allowed us to reach important conclusions regarding resistance pattern among *A. baumannii* isolates in our hospital, which has an implication for future work. Accordingly, we suggest conducting large-scale long-period prospective studies on molecular epidemiology of *A. baumannii* with emphasis on drug resistance, in order to determine the population structure and their antimicrobial resistance patterns.

In conclusion, our findings revealed that *A. baumannii* is an important human pathogen that is gradually gaining more attention as a public health threat in Qatar. The emergence of carbapenem resistance means that there is a need to look for alternatives such as colistin and tigecycline, which retained greatest activity against the *A. baumannii* isolates. Infection with MDR *A. baumannii* is independently associated with high mortality, emphasizing the need for aggressive infection control strategies to prevent MDR *Acinetobacter* infection and its adverse effects on hospitalized patients.

Competing Interests

The authors declare that they have no competing interests.

References

- [1] M. M. Kock, A. N. Bellomo, N. Storm, and M. M. Ehlers, "Prevalence of carbapenem resistance genes in *Acinetobacter baumannii* isolated from clinical specimens obtained from an academic hospital in South Africa," *Southern African Journal of Infectious Diseases*, vol. 28, pp. 28–32, 2013.
- [2] M. Wadl, K. Heckenbach, I. Noll et al., "Increasing occurrence of multidrug-resistance in *Acinetobacter baumannii* isolates from four german university hospitals, 2002–2006," *Infection*, vol. 38, no. 1, pp. 47–51, 2010.
- [3] W.-S. Leung, C.-M. Chu, K.-Y. Tsang, F.-H. Lo, K.-F. Lo, and P.-L. Ho, "Fulminant community-acquired *Acinetobacter baumannii* pneumonia as a distinct clinical syndrome," *Chest*, vol. 129, no. 1, pp. 102–109, 2006.
- [4] P. E. Fournier and H. Richet, "The epidemiology and control of *Acinetobacter baumannii* in health care facilities," *Clinical Infectious Diseases*, vol. 42, no. 5, pp. 692–699, 2006.
- [5] F. Y. Khan, M. Abukhattab, and K. Baager, "Nosocomial post-neurosurgical *Acinetobacter baumannii* meningitis: a retrospective study of six cases admitted to Hamad general hospital, Qatar," *Journal of Hospital Infection*, vol. 80, no. 2, pp. 176–179, 2012.
- [6] F. Y. Khan, S. S. Elshafie, M. Almaslamani et al., "Epidemiology of bacteraemia in Hamad general hospital, Qatar: a one year hospital-based study," *Travel Medicine and Infectious Disease*, vol. 8, no. 6, pp. 377–387, 2010.
- [7] C.-I. Kang, S.-H. Kim, B. P. Wan et al., "Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome," *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 2, pp. 760–766, 2005.

- [8] N. B. A. Ntusi, M. Badri, H. Khalfey et al., "ICU-associated *Acinetobacter baumannii* colonisation/infection in a high HIV-prevalence resource-poor setting," *PLoS ONE*, vol. 7, no. 12, Article ID e52452, 2012.
- [9] R. C. Bone, R. A. Balk, F. B. Cerra et al., "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine," *Chest*, vol. 136, no. 5, p. e28, 2009.
- [10] M. E. Falagas, P. K. Koletsis, and I. A. Bliziotis, "The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) *Acinetobacter baumannii* and *Pseudomonas aeruginosa*," *Journal of Medical Microbiology*, vol. 55, no. 12, pp. 1619–1629, 2006.
- [11] Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing: 24th informational supplement," CLSI M100-S21, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2011.
- [12] G. Rivera, J. Bulnes, C. Castillo, M. C. Ajenjo, P. García, and J. Labarca, "Extensively drug-resistant *Acinetobacter baumannii* isolated in a university hospital: role of inter-hospital transmission," *Journal of Infection in Developing Countries*, vol. 10, no. 1, pp. 96–99, 2016.
- [13] L. L. Maragakis and T. M. Perl, "*Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options," *Clinical Infectious Diseases*, vol. 46, no. 8, pp. 1254–1263, 2008.
- [14] J. Rodríguez-Baño, J. M. Cisneros, F. Fernández-Cuenca et al., "Clinical features and epidemiology of *Acinetobacter baumannii* colonization and infection in Spanish hospitals," *Infection Control and Hospital Epidemiology*, vol. 25, no. 10, pp. 819–824, 2004.
- [15] N. Jaggi, P. Sissodia, and L. Sharma, "*Acinetobacter baumannii* isolates in a tertiary care hospital: antimicrobial resistance and clinical significance," *Journal of Microbiology and Infectious Diseases*, vol. 2, pp. 57–63, 2012.
- [16] S. Begum, F. Hasan, S. Hussain, and A. A. Shah, "Prevalence of multi drug resistant *Acinetobacter baumannii* in the clinical samples from tertiary care hospital in Islamabad, Pakistan," *Pakistan Journal of Medical Sciences*, vol. 29, no. 5, pp. 1253–1258, 2013.
- [17] M. Chaudhary and A. Payasi, "Incidence, prevalence and control of multidrug resistant (MDR) carbapenemase producing *Acinetobacter baumannii* in Indian intensive care units," *Journal of Pharmacy Research*, vol. 7, no. 2, pp. 175–180, 2013.
- [18] N. Sinha, J. Agarwal, S. Srivastava, and M. Singh, "Analysis of carbapenem-resistant *Acinetobacter* from a tertiary care setting in North India," *Indian Journal of Medical Microbiology*, vol. 31, no. 1, pp. 60–63, 2013.
- [19] G. Mahajan, S. Sheemar, S. Chopra, J. Kaur, D. Chowdhary, and S. K. Makhija, "Carbapenem resistance and phenotypic detection of carbapenemases in clinical isolates of *Acinetobacter baumannii*," *Indian Journal of Medical Sciences*, vol. 65, no. 1, pp. 18–25, 2010.
- [20] A. Versporten, S. Coenen, N. Adriaenssens et al., "European surveillance of antimicrobial consumption (ESAC): outpatient cephalosporin use in Europe (1997–2009)," *Journal of Antimicrobial Chemotherapy*, vol. 67, no. 2, Article ID dkr530, pp. 518–518, 2012.
- [21] D. Gur, V. Korten, S. Unal, L. M. Deshpande, and M. Castanheira, "Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing *Acinetobacter baumannii*: report from the Turkish SENTRY Program sites," *Journal of Medical Microbiology*, vol. 57, no. 12, pp. 1529–1532, 2008.
- [22] H. Ziglam, O. Elahmer, S. Amri et al., "Antimicrobial resistance patterns among *Acinetobacter baumannii* isolated from burn intensive care unit in Tripoli, Libya," *International Arabic Journal of Antimicrobial Agents*, vol. 2, no. 3, 2012.
- [23] J. Moradi, F. B. Hashemi, and A. Bahador, "Antibiotic resistance of *Acinetobacter baumannii* in Iran: a systemic review of the published literature," *Osong Public Health and Research Perspectives*, vol. 6, no. 2, pp. 79–86, 2015.
- [24] H. Aydemir, G. Celebi, N. Piskin et al., "Mortality attributable to carbapenem-resistant nosocomial *Acinetobacter baumannii* infections in a Turkish university hospital," *Japanese Journal of Infectious Diseases*, vol. 65, no. 1, pp. 66–71, 2012.
- [25] L. Poirel and P. Nordmann, "Carbapenem resistance in *Acinetobacter baumannii*: Mechanisms and epidemiology," *Clinical Microbiology and Infection*, vol. 12, no. 9, pp. 826–836, 2006.
- [26] U. J. Kim, H. K. Kim, J. H. An, S. K. Cho, K. Park, and H. Jang, "Update on the epidemiology, treatment, and outcomes of carbapenem-resistant *Acinetobacter* infections," *Chonnam Medical Journal*, vol. 50, no. 2, pp. 37–44, 2014.
- [27] A. Ulu-Kilic, S. Ahmed, E. Alp, and M. Doğanay, "Challenge of intensive care unit-acquired infections and *Acinetobacter baumannii* in developing countries," *OA Critical Care*, vol. 1, no. 1, 2013.
- [28] J. W. Liu, L. S. Wang, Y. J. Cheng et al., "In-vitro activity of tigecycline against clinical isolates of *Acinetobacter baumannii* in Taiwan," *International Journal of Antimicrobial Agents*, vol. 32, supplement 3, pp. S188–191, 2008.
- [29] R. Ricciardi, A. M. Ricciardi, and G. Danzi, "In vitro activity of tigecycline against multidrug-resistant *Acinetobacter baumannii* clinical isolates," *Infezioni in Medicina*, vol. 17, no. 4, pp. 236–239, 2009.
- [30] S. Tiengrim, C. Tribuddharat, and V. Thamlikitkul, "In vitro activity of tigecycline against clinical isolates of multidrug-resistant *Acinetobacter baumannii* in Siriraj Hospital, Thailand," *Journal of the Medical Association of Thailand*, vol. 89, supplement 5, pp. S102–S105, 2006.
- [31] D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas, "Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) *Acinetobacter* infections: a review of the scientific evidence," *Journal of Antimicrobial Chemotherapy*, vol. 62, no. 1, pp. 45–55, 2008.
- [32] F. E. Ö. Akin, A. Bayram, and I. Balci, "Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant *Acinetobacter baumannii* isolates," *Mikrobiyoloji Bulteni*, vol. 44, no. 2, pp. 203–210, 2010.
- [33] Y. K. Park, S.-I. Jung, K.-H. Park et al., "Independent emergence of colistin-resistant *Acinetobacter* spp. isolates from Korea," *Diagnostic Microbiology and Infectious Disease*, vol. 64, no. 1, pp. 43–51, 2009.
- [34] M. Sinirtaş, H. Akalin, and S. Gedikoğlu, "Investigation of colistin sensitivity via three different methods in *Acinetobacter baumannii* isolates with multiple antibiotic resistance," *International Journal of Infectious Diseases*, vol. 13, no. 5, pp. e217–e220, 2009.
- [35] R. H. Sunenshine, M.-O. Wright, L. L. Maragakis et al., "Multidrug-resistant *Acinetobacter* infection mortality rate and length of hospitalization," *Emerging Infectious Diseases*, vol. 13, no. 1, pp. 97–103, 2007.